![Thomas Mehrling](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas Mehrling
Directeur Général chez
HELIX BIOPHARMA CORP.
Fortune : 50 290 $ au 31/07/2026
Profil
Thomas J.
Mehrling is the founder of Laevoroc Oncology AG, founded in 2019, where Dr. Mehrling holds the title of Chief Executive Officer.
Dr. Mehrling was the founder of Mundipharma EDO GmbH, founded in 2013, where Dr. Mehrling held the title of Chief Executive Officer.
Dr. Mehrling is also the founder of Laevoroc Immunology AG..
Dr. Mehrling is Chief Executive Officer at Release Therapeutics SA since 2024.
Dr. Mehrling is Chief Executive Officer at Helix BioPharma Corp.
starting in 2025.
Dr. Mehrling is Chairman & Chief Executive Officer at Laevoroc Chemotherapy AG.
Dr. Mehrling was Managing Director-European Oncology at Mundipharma International Ltd. from 2003 to 2013.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
HELIX BIOPHARMA CORP. 0,06 % | 21/05/2026 | 47 000 ( 0,06 % ) | 50 290 $ | 31/07/2026 |
Postes actifs de Thomas Mehrling
| Sociétés | Poste | Début |
|---|---|---|
| HELIX BIOPHARMA CORP. | Directeur Général | 10/04/2025 |
Laevoroc Oncology AG
 Laevoroc Oncology AG BiotechnologyHealth Technology Develops and manufactures cancer immunotherapies | Directeur Général | 01/02/2019 |
Release Therapeutics SA
 Release Therapeutics SA BiotechnologyHealth Technology Develops first cell microencapsulation technology to deliver therapeutic proteins beyond the human blood-brain barrier | Directeur Général | 27/06/2024 |
Anciens postes connus de Thomas Mehrling
| Sociétés | Poste | Fin |
|---|---|---|
Mundipharma EDO GmbH
 Mundipharma EDO GmbH Miscellaneous Commercial ServicesCommercial Services Engages in research and development of therapies for cancer | Directeur Général | 01/07/2019 |
Mundipharma International Ltd.
 Mundipharma International Ltd. Pharmaceuticals: MajorHealth Technology Develops and produces pharmaceutical products | Corporate Officer/Principal | 01/01/2013 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
23
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Helix BioPharma Corp.
 Helix BioPharma Corp. Pharmaceuticals: MajorHealth Technology Develops drugs for the prevention and treatment of cancer | Health Technology |
Mundipharma International Ltd.
Mundipharma International Ltd. Pharmaceuticals: MajorHealth Technology Develops and produces pharmaceutical products | Health Technology |
Release Therapeutics SA
Release Therapeutics SA BiotechnologyHealth Technology Develops first cell microencapsulation technology to deliver therapeutic proteins beyond the human blood-brain barrier | Health Technology |
Mundipharma EDO GmbH
Mundipharma EDO GmbH Miscellaneous Commercial ServicesCommercial Services Engages in research and development of therapies for cancer | Commercial Services |
Laevoroc Oncology AG
Laevoroc Oncology AG BiotechnologyHealth Technology Develops and manufactures cancer immunotherapies | Health Technology |
